Strong sales of Mounjaro, Zepbound push Lilly profits up 68%

Eli Lilly and Co. said Thursday strong sales of diabetes treatment Mounjaro, weight-loss treatment Zepbound and other drugs helped push second-quarter profit up 68% to $2.97 billion, and it raised full-year revenue guidance by $3 billion. The Indianapolis-based drugmaker said revenue increased 36% in the quarter to $11.3 billion. Zepbound, the popular obesity drug that launched in December, crossed into blockbuster territory, with sales of $1.23 billion in the quarter. Mounjaro, which was launched just two years ago, had sales of $3.09 billion, making it Lilly’s top-selling product. Cancer drug...